Therapeutic Polymer-Based Cannabidiol Formulation: Tackling Neuroinflammation Associated with Ischemic Events in the Brain

Mol Pharm. 2024 Apr 1;21(4):1609-1624. doi: 10.1021/acs.molpharmaceut.3c00244. Epub 2024 Feb 27.


Cannabidiol (CBD) is the most relevant nonpsychostimulant phytocompound found in Cannabis sativa. CBD has been extensively studied and has been proposed as a therapeutic candidate for neuroinflammation-related conditions. However, being a highly lipophilic drug, it has several drawbacks for pharmaceutical use, including low solubility and high permeability. Synthetic polymers can be used as drug delivery systems to improve CBD's stability, half-life, and biodistribution. Here, we propose using a synthetic polymer as a nanoparticulate vehicle for CBD (NPCBD) to overcome the pharmacological drawbacks of free drugs. We tested the NPCBD-engineered system in the context of ischemic events in a relevant oxygen and glucose deprivation (OGD) model in primary cortical cells (PCC). Moreover, we have characterized the inflammatory response of relevant cell types, such as THP-1 (human monocytes), HMC3 (human microglia), and PCC, to NPCBD and observed a shift in the inflammatory state of the treated cells after the ischemic event. In addition, NPCBD exhibited a promising ability to restore mitochondrial function after OGD insult in both HMC3 and PCC cells at low doses of 1 and 0.2 μM CBD. Taken together, these results suggest the potential for preclinical use.

Keywords: cannabidiol; neuroinflammation; oxygen and glucose deprivation; poly(lactic-co-glycolic acid); stroke.

MeSH terms

  • Brain
  • Cannabidiol* / pharmacology
  • Cannabidiol* / therapeutic use
  • Humans
  • Neuroinflammatory Diseases
  • Oxygen
  • Tissue Distribution


  • Cannabidiol
  • Oxygen